Please Wait.....
Report
Complicated Urinary Tract Infections - Epidemiology Forecast - 2032
Market Report I 2022-08-01 I 122 Pages I DelveInsight
DelveInsight's " Complicated Urinary Tract Infection (cUTI)- Epidemiology Forecast-2032" report delivers an in-depth understanding of the Complicated Urinary Tract Infection, historical and forecasted epidemiology as well as the Complicated Urinary Tract Infection trends in the United States, EU-5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Geography Covered
- The United States
- EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
Complicated Urinary Tract Infection (cUTI) Understanding
The DelveInsight's Complicated Urinary Tract Infection epidemiology report gives a thorough understanding of Complicated Urinary Tract Infection. Urinary tract infections (UTIs) are amongst the most frequent bacterial infections. They can manifest clinically in various ways, from relatively benign, uncomplicated infections to complicated UTIs (cUTIs), pyelonephritis, and severe urosepsis. cUTI is a heterogeneous entity comprising multiple forms.
Several classification systems exist for the description and classification of UTIs, with the common rationale that cUTIs have a higher risk of recurrence or chronification, progression, or severe outcome than uncomplicated UTIs. High antibiotic resistance rates among the causing bacteria are linked to cUTIs and pyelonephritis.aHUS is a disease that primarily affects kidney function. This condition, which can occur at any age, causes abnormal blood clots (thrombi) to form in small blood vessels in the kidneys. These clots can cause serious medical problems if they restrict or block blood flow. It is characterized by three major features related to abnormal clotting: hemolytic anemia, thrombocytopenia, and kidney failure.
The colonization of the urogenital tract by rectal and perineal flora is the primary cause of UTIs. Escherichia coli, Enterococcus, Klebsiella, Pseudomonas, and other Enterococcus or Staphylococcus species are among the most prevalent microorganisms; the most frequent of them is Escherichia coli, followed by Klebsiella. Candida can colonize individuals receiving residential care, diabetics, those with indwelling catheters, and people with any type of immune impairment.
Patients prone to infection risks tend to get cUTIs more frequently. The likelihood of a cUTI may be increased by the following: age, particularly that of older people and small children, diabetes, renal illness, cancerous bladder blockage, pregnancy with a compromised immune system, and an underlying urologic problem that was recently treated with a catheter.
Despite the frequency of UTIs present in hospitals, they (especially cUTIs) continue to be a clinical entity that causes major confusion, diagnostic ambiguity, and a source of large inappropriate antibiotic prescriptions.
The most crucial clinical criteria for the first diagnosis of a UTI are symptoms, such as increased urinary frequency, urgency, hematuria, dysuria, suprapubic or flank discomfort. Additionally, there must be a suitable clinical scenario in which the most likely cause of these symptoms is an infection of the urogenital tract.
First-line antibiotics should be used to begin empiric therapy in this circumstance. Before initiating therapy, a urine sample should be sent for microscopy and culture. Severe cUTIs can present as severe undifferentiated sepsis or even septic shock.
Pharmacotherapy aims to eradicate the infection, prevent complications, and provide symptomatic relief to patients. Early treatment is recommended to reduce the risk of progression to pyelonephritis. The treatment goals are to get rid of the infection, prevent complications, and help provide symptomatic relief. In order to lower the risk of developing pyelonephritis, early treatment is recommended. When considering empirical antimicrobial selection, it is critical to recognize antimicrobial resistance trends. The main course of treatment for individuals with lower UTIs is an oral medication with an empirically selected antibiotic that is effective against Gram-negative aerobic coliform bacteria, such as Escherichia coli. Currently, there are several types of medications used for treatment purposes, namely beta-lactamase inhibitors, protein synthesis inhibitors, and others. At times, combination therapy and dietary supplementation are also prescribed.
Complicated Urinary Tract Infection (cUTI) Epidemiology
The epidemiology section provides insights about the historical and current Complicated Urinary Tract Infection patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides a historical as well as forecasted Complicated Urinary Tract Infection epidemiology scenario in the 7MM covering the United States, EU-5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
In the year 2021, the total diagnosed incident cases of cUTI were 8.08 Million (M) in the 7MM which are expected to grow during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted Complicated Urinary Tract Infection epidemiology [segmented as Total Diagnosed-incident Cases of Complicated Urinary Tract Infection, Total Age-specific Cases of Complicated Urinary Tract Infection, Total Pathogen-specific Cases of Complicated Urinary Tract Infection, and Total Treated Cases (across lines) of Complicated Urinary Tract Infection] in the 7MM covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.?
Country Wise- Complicated Urinary Tract Infection (cUTI) Epidemiology
The epidemiology segment also provides the Complicated Urinary Tract Infection epidemiology data and findings across the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
According to the DelveInsight, in the year 2021, the total diagnosed incident cases of cUTI were 3.43 M in the United States which are expected to grow during the study period, i.e., 2019-2032.
The highest number of total incident cases of cUTI was observed in Germany among the EU5 countries with 0.87 M cases in 2021 which are expected to grow during the study period, i.e., 2019-2032.
In the year 2021, the total diagnosed incident cases of cUTI were 1.28 M in Japan which are expected to grow during the study period, i.e., 2019-2032.
KOL- Views
To keep up with the current Complicated Urinary Tract Infection patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Complicated Urinary Tract Infection domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.
Scope of the Report
- The report covers the descriptive overview of Complicated Urinary Tract Infection, explaining their causes, symptoms, pathophysiology, and genetic basis.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- The report assesses the disease risk and burden and highlights the unmet needs of Complicated Urinary Tract Infection.
- The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
- The report provides the segmentation of the disease epidemiology for 7MM total diagnosed-incident cases of complicated urinary tract infection, total age-specific cases of complicated urinary tract infection, total pathogen-specific cases of complicated urinary tract infection, and total treated cases (across lines) of complicated urinary tract infection in the 7MM covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Complicated Urinary Tract Infection R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Complicated Urinary Tract Infection.
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Complicated Urinary Tract Infection (cUTI) Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Complicated Urinary Tract Infection Epidemiology Segmentation
Key Questions
Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of Complicated Urinary Tract Infection?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU-5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical Complicated Urinary Tract Infection patient pool in seven major markets covering the United States, EU-5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Complicated Urinary Tract Infection in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM concerning the patient population about Complicated Urinary Tract Infection?
- Out of all 7MM countries, which country would have the highest prevalent population of Complicated Urinary Tract Infection during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Complicated Urinary Tract Infection Disease market
- To understand the future market competition in the Complicated Urinary Tract Infection Disease market
- Organize sales and marketing efforts by identifying the best opportunities for Complicated Urinary Tract Infection Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for the Complicated Urinary Tract Infection Disease market
- To understand the future market competition in the Complicated Urinary Tract Infection Disease market
1. Key Insights
2. Report Introduction
3. Table of Contents
4. Complicated Urinary Tract Infection (cUTI) Market Overview at a Glance
4.1. Market Share (%) Distribution of cUTI in 2019
4.2. Market Share (%) Distribution of cUTI in 2032
4.3. Market Share (%) Distribution of Cephalosprin in cUTI by generation in 2019
4.4. Market Share (%) Distribution of Cephalosprin in cUTI by generation in 2032
5. Executive Summary of Complicated Urinary Tract Infection (cUTI)
6. Key Events
6.1. Future Prospectus
7. Epidemiology and Market Methodology
8. Disease Background and Overview
8.1. Introduction
8.2. Classification of UTI
8.3. Signs and Symptoms of cUTIs
8.4. Risk Factors and Causes
8.5. Pathophysiology of cUTIs
8.6. Complications
8.7. Diagnosis of cUTIs
8.7.1. Differential diagnosis (DDx)
8.8. Diagnostic Guidelines for Complicated Urinary Tract Infection
8.8.1. The European Association of Urology Guidelines for Diagnosis of cUTIs
8.8.2. Infectious Diseases Society of America (IDSA) Guidelines for the Diagnosis and Treatment of Asymptomatic Bacteriuria (ASB) in Adults
8.8.3. NICE Guidelines for diagnosis of UTI in infants and children
9. Treatment and Management of cUTIs
9.1.1. Antibiotic resistance in cUTI
9.2. Treatment Guidelines for Complicated Urinary Tract Infection
9.2.1. The European Association of Urology (EAU) Guidelines for Treatment of cUTIs
9.2.2. NICE Guidelines for the management of cUTIs
9.3. Diagnostic and Treatment Algorithm for cUTI
10. Epidemiology and Patient Population
10.1. Key Findings
10.2. Assumptions and Rationale
10.3. Epidemiology Scenario in the 7MM
10.3.1. Total Diagnosed incident Cases of Complicated Urinary Tract Infection (cUTI) in the 7MM
10.3.2. Total Age-specific Cases of Complicated Urinary Tract Infection in the 7MM
10.3.3. Total Pathogen-specific Cases of Complicated Urinary Tract Infection in the 7MM
10.3.4. Total Treated Cases (across lines) of Complicated Urinary Tract Infection in the 7MM
10.4. Epidemiology Scenario in the United States
10.4.1. Total Diagnosed-incident Cases of Complicated Urinary Tract Infection in the US
10.4.2. Total Age-specific Cases of Complicated Urinary Tract Infection
10.4.3. Total Pathogen-specific Cases of Complicated Urinary Tract Infection
10.4.4. Total Treated Cases (across lines) of Complicated Urinary Tract Infection
10.5. Epidemiology Scenario in the EU-5 Countries
10.5.1. Total Diagnosed-incident Cases of Complicated Urinary Tract Infection in EU-5
10.5.2. Total Age-specific Cases of Complicated Urinary Tract Infection in EU-5
10.5.3. Total Pathogen-specific Cases of Complicated Urinary Tract Infection in EU-5
10.5.4. Total Treated Cases (across lines) of Complicated Urinary Tract Infection in EU-5
10.6. Epidemiology Scenario in the Japan
10.6.1. Total Diagnosed-incident Cases of Complicated Urinary Tract Infection (cUTI) in Japan
10.6.2. Total Age-specific Cases of Complicated Urinary Tract Infection in Japan
10.6.3. Total Pathogen-specific Cases of Complicated Urinary Tract Infection in Japan
10.6.4. Total Treated Cases (across lines) of Complicated Urinary Tract Infection in Japan
11. Unmet Needs
12. Appendix
12.1. Bibliography
12.2. Report Methodology
13. DelveInsight Capabilities
14. Disclaimer
15. About DelveInsight
Table 1: Summary of Complicated Urinary Tract Infection (cUTI), Market, Epidemiology, and Key Events (2019-2032)
Table 2: Organisms commonly found infecting cUTI patients
Table 3: Treatment Regimens for Complicated UTI (known organism and susceptibility)
Table 4: Summary of evidence for the treatment of complicated UTIs
Table 5: Summary of Recommendations for the treatment of complicated UTIs
Table 6: Choice of antibiotic
Table 7: Choice of antibiotic
Table 8: Total Diagnosed-incident Cases of cUTI (in Thousands) in the 7MM(2019-2032)
Table 9: Total Diagnosed-incident Cases of cUTI progressed from uUTI (in Thousands) in the 7MM (2019-2032)
Table 10: Total Age-specific Cases of cUTI (in Thousands) in the 7MM (2019-2032)
Table 11: Total Pathogen-specific Cases of cUTI (in Thousands) in the 7MM (2019-2032)
Table 12: Total Treated Cases of cUTI (in Thousands) in the 7MM (2019-2032)
Table 13: Total Diagnosed-incident Cases of cUTI (in Thousands) in the US (2019-2032)
Table 14: Total Diagnosed-incident Cases of cUTI progressed from uUTI (in Thousands) in the US (2019-2032)
Table 15: Total Age-specific Cases of cUTI (in Thousands) in the US (2019-2032)
Table 16: Total Pathogen-specific Cases of cUTI (in Thousands) in the US (2019-2032)
Table 17: Total Treated Cases of cUTI (in Thousands) in the US (2019-2032)
Table 18: Total Diagnosed-incident Cases of cUTI (in Thousands) in EU-5 (2019-2032)
Table 19: Total Diagnosed-incident Cases of cUTI progressed from uUTI (in Thousands) in EU-5 (2019-2032)
Table 20: Total Age-specific Cases of Complicated Urinary Tract Infection (in Thousands) in EU-5 (2019-2032)
Table 21: Total Pathogen-specific Cases of Complicated Urinary Tract Infection (in Thousands) in EU-5 (2019-2032)
Table 22: Total Treated Cases of cUTI (in Thousands) in EU-5 (2019-2032)
Table 23: Total Diagnosed-incident Cases of cUTI (in Thousands) in Japan (2019-2032)
Table 24: Total Diagnosed-incident Cases of cUTI progressed from uUTI (in Thousands) in Japan (2019-2032)
Table 25: Total Age-specific Cases of cUTI(in Thousands) in Japan(2019-2032)
Table 26: Total Pathogen-specific Cases of cUTI (in Thousands) in Japan(2019-2032)
Table 27: Total Treated Cases of cUTI (in Thousands) in Japan(2019-2032)
Figure 1: Epidemiology and Market Methodology
Figure 2: Urinary System
Figure 3: Classification of UTI
Figure 4: The European Section of Infections in Urology classification of UTIs
Figure 5: Common Symptoms of UTIs
Figure 6: Pathophysiological aspects of complicated UTI and pyelonephritis
Figure 7: Algorithm for Diagnosis and Treatment of cUTI
Figure 8: Algorithm for evaluating a woman with symptoms of Acute UTI
Figure 9: Total Diagnosed-incident Cases of cUTI in the 7MM (2019-2032)
Figure 10: Total Diagnosed-incident Cases of cUTI progressed from uUTI in the 7MM (2019-2032)
Figure 11: Total Age-specific Cases of cUTI in the 7MM (2019-2032)
Figure 12: Total Pathogen-specific Cases of cUTI in the 7MM (2019-2032)
Figure 13: Total Treated Cases (across the line) of cUTI in the 7MM (2019-2032)
Figure 14: Total Diagnosed-incident Cases of cUTI in the US (2019-2032)
Figure 15: Total Diagnosed-incident Cases of cUTI progressed from uUTI in the US (2019-2032)
Figure 16: Total Age-specific Cases of cUTI in the US (2019-2032)
Figure 17: Total Pathogen-specific Cases of cUTI in the US (2019-2032)
Figure 18: Total Treated Cases (across the line) of cUTI in the US (2019-2032)
Figure 19: Total Diagnosed-incident Cases of cUTI in EU-5 (2019-2032)
Figure 20: Total Diagnosed-incident Cases of cUTI progressed from uUTI in EU-5 (2019-2032)
Figure 21: Total Age-specific Cases of cUTI in EU-5 (2019-2032)
Figure 22: Total Pathogen-specific Cases of Complicated Urinary Tract Infection in EU-5 (2019-2032)
Figure 23: Total Treated Cases (across the line) of cUTI in EU-5 (2019-2032)
Figure 24: Total Diagnosed-incident Cases of cUTI in Japan (2019-2032)
Figure 25: Total Diagnosed-incident Cases of cUTI progressed from uUTI in Japan (2019-2032)
Figure 26: Total Age-specific Cases of cUTI in Japan (2019-2032)
Figure 27: Total Pathogen-specific Cases of cUTI in Japan (2019-2032)
Figure 28: Total Treated Cases (across the line) of cUTI in Japan (2019-2032)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security